Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of FZ002 in Healthy Adults
NCT07649096Phase 1Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FZ002 in Clostridioides difficile infection (CDI) (8 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Serious Adverse Events at Day 208, Solicited Adverse Events at Day 35 and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
FZ002
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT07649096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07649096.